The aims of the present study were to describe the consumption trends of three groups of analgesics (non-opioids, and mild and strong opioids) between 2006 and 2015 in France, and compare this pattern of use with six European countries in 2015.
Introduction
Pain is a common issue, and analgesics are among the drugs most frequently used, especially in self-medication [1] . A variety of analgesics, with different clinical potencies, are available on the market. According to the World Health Organization's (WHO) three-step ladder for cancer pain relief in adults [2] , analgesics are categorized into: (i) non-opioids; (ii) mild opioids; and (iii) strong opioids. Opioids initially used for severe and acute pain management are known to lead potentially to dependence and misuse [3, 4] . Opioid use has spread gradually to noncancer chronic pain, raising safety concerns [5] . The use of non-opioids is also a matter of concern, especially for over-the-counter (OTC) drugs that can cause adverse drug reactions and increase risks of intoxication [6] [7] [8] .
Sales of analgesics have risen steadily over the past 20 years in Europe [9] [10] [11] [12] . Indeed, in France, analgesics were the most used therapeutic class within primary care settings in 2013 (22% of the market share for all medications) [13] . Paracetamol was the most consumed medication, with more than 500 million packs sold, followed by ibuprofen, codeine combinations and tramadol, alone or as a fixed-dose combination. Between 2006 and 2015, paracetamol was available over the counter, and ibuprofen and codeine benefited from being both prescription-only (POMs) and OTC medicines, whereas tramadol was only available as a POM. Paracetamol was the most widely prescribed drug in France in this period [14, 15] as a result of its better safety profile compared with other analgesics [16] .
Monitoring sales of analgesics has different purposes. By describing the consumption trends of different substances, the effects of withdrawing problematic drugs and of the release of new drugs onto the market can be analysed. This helps to ensure that guidelines promoting the safe use and management of drugs are well implemented in clinical practice. It can also help to identify the most used substances requiring further surveillance, and could support studies on misuse.
The present study therefore aimed to: (i) describe the consumption trends of all three groups of analgesics in France between 2006 and 2015, in order to analyse structural and quantitative changes in use; and (ii) compare patterns of use with other European countries in 2015. It was intended that these results would provide a comprehensive view of analgesics, regardless of their planned use: acute pain, noncancer chronic pain and cancer chronic pain, and would reveal patterns of switching from one group to another.
Methods

Data sources
Annual drug sales in France (including the five French overseas departments: Guadeloupe, Martinique, French Guiana, Réunion, Mayotte) were extracted from the Agence Nationale de Sécurité des Médicaments (ANSM) database on consumption for the 2006-2015 period. This database comprises comprehensive reporting of annual pack sales provided each year from pharmaceutical firms to the ANSM. It contains data on sales to wholesalers, community pharmacies (retail) and hospitals (nonretail).
We purchased annual drug sales data from the IMS Multinational Integrated Data Analysis System (MIDAS) (IMS Health, Danbury, CT, USA) for the five most populated countries in Europe: Germany, France, UK, Italy and Spain. This database provides an estimate of drug sales in a country (estimated product volumes, trends and market share by product and therapeutic class), through retail and nonretail channels. In this database, drug sales are measured using standard units (i.e. the number of counting units sold, divided by the standard unit factor, which is the smallest common dose of a product form) [17] . The present analysis focused on 2015 data. Supplementary data on doses were also retrieved from the respective national databases in each country. Data on analgesic consumption in Denmark and Sweden for 2015 were extracted online from the Danish Health Data Authority and the National Board of Health and Welfare in Sweden (www.medstat.dk and www. socialstyrelsen.se, respectively). For these two countries, the data cover all sales in both sectors (retail and nonretail) and are available directly in defined daily dose per 1000 inhabitants per day (DDD 1000 inhabitants -1 day -1 ).
Analgesics
Analgesics were categorized according to the WHO's three-step ladder [2] [19] . Trends in analgesic use were expressed, for the most commonly used drugs in each group, as the percentage of change in consumption (global variation rates) between 2006 and 2015. Additional analyses were performed for OTC and prescription analgesics (i.e. aspirin, paracetamol and ibuprofen) according to the formulations and doses, to describe trends among paediatric and adult populations.
Qualitative comparisons of analgesic consumption between the seven European countries in 2015 were performed for all drugs with marketing authorization in France. A chi-square test was used for quantitative comparisons, with P-values ≤0.05 considered significant. An analysis was performed, including both those released in France and all others released in Europe (i.e. metamizole, meptazinol, diflunisal, tilidine, propyphenazone, flupirtine, dexibuprofen and lornoxicam).
Results
Consumption trends in France
During the 10-year study period in France, the total consumption of analgesics showed a slight decrease of 7%, falling from 133 DDDs 1000 inhabitants 
Figure 1
Consumption of all three groups of analgesics in France, 2006-2015. DDD, defined daily dose groups of analgesics (data not shown), although the mean consumption during the study period was higher in primary care (20-, 24-and fourfold higher for non-opioids, and mild and strong opioids, respectively).
Non-opioids
The trends in non-opioid use are presented in Figure 2 . Paracetamol was the most consumed substance, with a continuous increase in use between 2006 and 2015 (+53%).
There was a nearly twofold decrease in the consumption of aspirin (from 3.8 to 2 DDDs 1000 inhabitants
whereas the use of ibuprofen and other NSAIDs remained relatively stable. Considering the doses of the drugs, consumption trends for OTC or prescription-only non-opioids revealed that the 1000 mg tablets of paracetamol have been the most used drug among adults since 2008 (Figure 3a) . Their consumption increased over the 10-year period (+140%), whereas consumption of the 500 mg tablet pack decreased by 20%. Ibuprofen was the second most used drug, showing increased use for the 400 mg tablets. By contrast, there was a decrease in the use of 200 mg ibuprofen and aspirin (oral route) (À48% and À68%, respectively). Trends for paediatric formulations were less stable over the period considered. The use of paracetamol and ibuprofen (oral route) was clearly higher than that of aspirin (Figure 3b ). The use of paediatric oral suspensions of paracetamol increased by 39%, in contrast to the use of aspirin (oral route) (À57%) and ibuprofen (10%).
For adult and paediatric formulations of paracetamol, rectal administration was mostly used in primary care, and this decreased by 35% over the 10-year period. By contrast, there was a nearly threefold increase in parenteral administration of paracetamol (mostly used in hospital settings).
Opioids
The consumption of mild opioids between 2006 and 2015 in France is presented in Figure 4 . Dextropropoxyphene combinations were the most widely used mild opioids in 2006, but there was a twofold decrease in consumption until 2010, the year prior to its withdrawal. Tramadol (alone or in combination use) and codeine combinations were the second and third most commonly used mild opioids, respectively, showing increased consumption over the 10-year period (+62% and +42%, respectively). Opiate combinations also showed a twofold increase in consumption, reaching 4. À11%) . The use of oxycodone increased dramatically by 613% (from 0.12 to 0.85 DDDs inhabitants -1 day -1 ). There was also a considerable increase in fentanyl consumption for both the transmucosal and transdermal forms (+263% and +72%, respectively). The use of other strong opioids (nalbuphine, pethidine and buprenorphine) was much lower (<1% of the total consumption of strong opioids) and tended to decrease over the 10-year period (data not shown).
Comparison of analgesic use in Europe in 2015
Overall Figure 6 ). France ranked first for paracetamol consumption, followed by Denmark, the UK and Spain. The consumption share of ibuprofen among total non-opioids was significantly lower in France compared with most other countries (11% vs. 59%, 32% and 25%, for Germany, Spain and Denmark, respectively; P ≤ 0.05 for all), whereas other NSAIDs and aspirin were used at similar levels. Figure 7 presents the opioid consumption of European countries for 2015. There was a clear higher use of both mild and strong opioids in the UK compared with other countries, primarily due to codeine in combination with paracetamol, and oral route/injectable morphine (accounting for 62% and 75% of mild and strong opioid use, respectively). France ranked third for mild opioid consumption, with tramadol (alone or in combination use) being the most used substance (48%). For the other countries, the most commonly used mild opioids were tramadol (alone or in combination use) in Germany, Italy, Spain and Denmark (98%, 82%, 78% and 85%, respectively), and codeine in combination with paracetamol in Sweden (54%).
France had the lowest consumption of strong opioids (3.2 DDDs 1000 inhabitants -1 day -1 ), along with Italy, with fentanyl being the main substance used (38%). Fentanyl also represented the most commonly used strong opioid in Germany and Italy (40% and 42%, respectively), whereas morphine (oral route/injectable), oxycodone and buprenorphine were the most used drugs in Denmark (40%), Sweden (41%) and Spain (47%). An analysis including analgesics that were not released in France showed similar patterns of use (data not shown).
Discussion
The results from the present study highlighted changes in analgesic consumption patterns in France over the past 10 years, characterized by the decreasing use of dextropropoxyphene combinations, along with an increase in the use of paracetamol (particularly the high dose for adults), other mild opioids (tramadol) and strong opioids (oxycodone, fentanyl). Patterns of analgesic consumption differed across Europe in 2015. France's non-opioid consumption was clearly highest, with paracetamol being the most consumed drug, but its use of strong opioids was among the lowest.
Figure 6
Consumption of non-opioids in seven European countries in 2015 K. Hider-Mlynarz et al.
The changing pattern of analgesic consumption observed for France in the present study is consistent with previous reports from France [20, 21] and Europe [10, [21] [22] [23] [24] . Withdrawal and new releases of marketed drugs may have accounted for the changing consumption patterns. In France, two analgesic drugs have been withdrawn successively: noramidopyrine (metamizole) in 2003 and dextropropoxyphene/paracetamol in 2011. The decrease in the consumption of mild opioids up to 2011 is likely to be explained by the gradual reduction in the use of dextropropoxyphene combinations until their definitive withdrawal from the French market, as recommended by the European Medicines Agency [25] . As their benefits did not outweigh their risks, such as the risk of death from overdose in patients taking these medicines, their withdrawal across the European Union was announced in 2009. A study conducted in the UK suggested that this measure was effective at reducing suicides [26] . The level of consumption of dextropropoxyphene combinations found in the present study was similar to that found for 2009 in another French study (25 DDDs 1000 inhabitants -1 day -1 ) [21] . Concomitant with the withdrawal of dextropropoxyphene combinations, national authority guidelines were published in 2011, recommending a switch to paracetamol for mild to moderate pain, and to NSAIDs, other mild opioids or strong opioids for more intense pain [27] . Prior to the publication of these guidelines, an impact study conducted in a French regional hospital had suggested that there may have been a switch towards the use of paracetamol and tramadol as a consequence of the withdrawal of dextropropoxyphene combinations [28] . A further survey conducted among prescribers involved in pain management confirmed this switch [29] . In our study, the increased consumption of paracetamol, ibuprofen and other mild opioids, was likely to result from the implementation of these guidelines by prescribing physicians. Paracetamol was found to be the most consumed analgesic in France in 2015 (61.5 DDDs 1000 inhabitants
representing 64% of the total market share for analgesics. This high consumption rate is consistent with previous findings [15, 30] , and with the fact that paracetamol is perceived as safe and is considered as the first-choice treatment for chronic pain [31, 32] . The OTC availability of paracetamol may also contribute to its high consumption. However, prescriptions of paracetamol have previously been estimated to account for 84% of paracetamol sales in France [15] , so selfmedication seems only partly to explain the high consumption observed in the present study. In our study, the significant increase in the use of the 1000 mg dose of paracetamol highlights the need specifically to monitor the sales or prescriptions of these packs [33, 34] . The risk of overdose is higher when the 1000 mg formulation is used several times a day. Changes in opioid consumption have previously been described worldwide [35] . In Europe, these were characterized by increasing use of tramadol, fentanyl and oxycodone [20] [21] [22] [23] [24] [36] [37] [38] . In Scandinavian countries, the total amount of opioids consumed increased from 2002 to 2006, due to a clear increase in fentanyl and oxycodone use, whereas the use of morphine decreased [23] . In Spain, a 14-fold increase in opioid use was recorded between 1992 and 2006, mainly attributable to an increase in prescriptions of fentanyl and tramadol [38] . Moreover, a fivefold increase in opioid [24] . Between 2000 and 2010, a large increase in opioid retail sales was also observed in Italy for tramadol (+299%) and codeine (+270%) [36] , and the prevalence of extended-release opioids increased in Germany by 103% for tramadol and almost fourfold for fentanyl, oxycodone, hydromorphone and buprenorphine [39] . The increased use of strong opioids was found to be mainly due to a sevenfold increase in oxycodone consumption, attaining the same market share of strong opioids as morphine in 2015 (32%).
Oxycodone was launched on the French market in 2002 and may therefore have replaced, together with fentanyl, part of the market share of morphine. As both opioids have similar efficacy and adverse effects, pharmaceutical marketing policies have been proposed as the most likely explanation for the dramatic rise in oxycodone consumption [23, 40] . Although the more suitable use of opioids to treat cancer pain contributed to their increased use, the fear of using morphine that can be associated with the terminal phase of illnesses ('morphinophobia') [41] has also been suggested as an explanation for the switch to other opioids such as fentanyl or oxycodone [38] . However, the prescription of opioids remains tricky for healthcare professionals for noncancer pain. Prescribers have to take into account, simultaneously, the aim of the prescription, the adverse effects of opioids and the protection of society from opioid misuse [42] . Moreover, nonrational prescription of oxycodone certainly has had a part in the growing consumption of opioids; besides its medical use for pain, further dependence might appear. Thus, the nonrational prescription of opioids grows, increasing the risk of public health consequences [43] . The ease of administration of transdermal and transmucosal formulations may also partly explain the rise in prescriptions of fentanyl [29] .
Apart from the ANSM's guidelines following the withdrawal of dextropropoxyphene combinations, pain management policies and guidelines emphasizing the use of opioids for noncancer pain [44] have probably contributed to the increased consumption of opioids. Furthermore, although prescriptions of opioids are beneficial for managing chronic pain, they often lead to misuse [12, 45] . In the United States, the recent example of the 'opioid epidemic' led the Centers for Disease Control and Prevention to draw up new opioid prescribing guidelines for the treatment of chronic pain in adults [46, 47] . Successive French Health Ministry action plans for improved pain management have been applied since 1998. The third, implemented in 2006-2010, helped to improve care and prevent acute pain, especially in children and the elderly.
Recent studies from claims databases have highlighted that opioids were mainly prescribed for noncancer pain in France and the UK [22, 37, 48] . Other possible explanations for the increase in opioid use include a rising prevalence of specific painful conditions [49] and misuse [50, 51] .
The difference in analgesic preferences observed between European countries in the present study may reflect the role of national guidelines, prescription policies and the marketing strategies of pharmaceutical companies, which can differ between these countries [40] , but it can also be explained by cultural backgrounds and local traditions in managing chronic pain [52, 53] .
Certain limitations must be acknowledged, however, such as a lack of information on the context of use. Firstly, although DDD is the recommended methodology, it represents a standard measure that may not reflect the real dose consumed. Moreover, the sales data used only provided information on the 'apparent consumption' and not on the 'real consumption': the proportion of these sales that is kept in stock and will be never used cannot be ascertained. We assumed that DDDs were reliable at least for opioids, as drugs dispensed to relieve intense pain should be consumed; however, we cannot estimate the proportion of abuse or misuse. Secondly, apart from analgesia, paracetamol is also indicated for fever. A study from the French adult population claims database showed that paracetamol was dispensed along with antibiotics in 40% of prescriptions [30] , meaning that nearly half the reimbursed consumption of paracetamol may not reflect pain management. Thirdly, it was not possible to differentiate the reason for the use of the analgesic (acute or chronic pain conditions). Nonetheless, the strengths of our study include the use of comprehensive national data on analgesic consumption within both primary care and hospital settings in France over a 10-year period, and the fact that the analysis of drug sales took into account analgesics that are available as both OTC and POM preparations. It is, however, impossible to measure the proportion of nonprescribed and prescribed OTC drugs.
To our knowledge, this was the first published study to analyse consumption trends both for non-opioids and opioids over the past decade in France. It showed that long-term surveillance over the past 10 years has highlighted quantitative and qualitative changes in analgesic consumption patterns in France, which are likely to have resulted from the withdrawal of dextropropoxyphene combinations, along with the implementation of national guidelines. Despite the existence of European regulations for medications and the common withdrawal of dextropropoxyphene combinations across Europe, there were very different patterns of consumption between countries in 2015. Out of the countries we studied, France clearly showed the highest use of paracetamol, especially the high dose for adults, and its use of oxycodone increased sevenfold, although it remained the country with the lowest consumption of strong opioids. Further surveillance studies are required, particularly to monitor the trends of these two drugs in France. The widespread consumption of analgesics raises the concern of overuse [54] , as well as addiction and misuse (approximately 10% and 25% of opioids users, respectively) [55] . Therefore, consideration of therapeutic indications may be useful for monitoring user profiles and trends of misuse, and to carry out appropriate preventive measures (e.g. the education of patients and health professionals, to increase the appropriateness of medication use and early detection of misuse).
